Novartis said the National Medical Products Administration approved the radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan injection) in combination with androgen receptor pathway inhibitors (ARPI) for PSMA‑positive metastatic hormon

2026-08-25

Novartis said the National Medical Products Administration approved the radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan injection) in combination with androgen receptor pathway inhibitors (ARPI) for PSMA‑positive metastatic hormone‑sensitive prostate cancer (mHSPC) in China.